B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

The antibody PLT012 targets the fat transporter CD36 to restore immune responses in tumors, offering a new and promising approach to treating immunotherapy-resistant cancers. A new study from Ludwig ...

Dry eye disease metrics, such as NIBUT and MG dropout, may serve as predictive biomarkers for possible thyroid disorders.

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Despite the well-recognized involvement of immunoglobulin (Ig) A in mucosal immunity, the function of its receptor ... The Immunoglobulin Receptors and their Physiological and Pathological ...

As developing antibody activators historically require extensive engineering after discovery, Nabla said their computational-first approach is a meaningful step toward compressing timelines and ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

They provide a first line of defense against infections, probably serve housekeeping functions and contribute ... forming pathogenic antigen–antibody (immune) complexes. These autoantibodies ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.